Generex to co-develop buccal aerosol formulation of leuprolide for NHTherapeutics

Generex Biotechnology has announced an agreement with NHTherapeutics to co-develop a formulation of leuprolide for delivery by Generex’s RapidMist buccal aerosol technology. Leuprolide is a gonadotropin-releasing hormone (GnRH) analog which is currently approved at higher dosage levels for the treatment of conditions such as prostate cancer and endometriosis; NHT is developing a lower dose formulation . . . Read more

FDA approves Stiolto Respimat for the treatment of COPD

According to Boehringer Ingelheim, the FDA has approved its tiotropium bromide/olodaterol soft mist inhaler for the treatment of COPD. The company filed an NDA for the product, which will be marketed as Stiolto Respimat Inhalation Spray, in August 2014. New data analyses from Phase 3 studies showing improved lung function for patients using the combination . . . Read more

Positive results from Phase 3 trials of NVA237 and QVA149

Novartis has announced positive results from several Phase 3 studies of NVA237 glycopyrronium bromide and QVA149 indacaterol/glycopyrronium bromide, both delivered by the Breezhaler DPI for the treatment of COPD. NVA237 is marketed as Seebri Breezhaler outside of the US, and QVA149 is marketed as Ultibro Breezhaler outside of the US. According to the data presented . . . Read more